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Abstract
Background: T cell immunoglobulin-3 (TIM-3) has been established as a negative regulatory molecule and plays a critical
role in immune tolerance. TIM-3 is upregulated in exhausted CD8
+ T cells in both chronic infection and tumor. However, the
nature of TIM-3
+CD4
+ T cells in the tumor microenvironment is unclear. This study is to characterize TIM-3 expressing
lymphocytes within human lung cancer tissues and establish clinical significance of TIM-3 expression in lung cancer
progression.
Methodology: A total of 51 human lung cancer tissue specimens were obtained from pathologically confirmed and newly
diagnosed non-small cell lung cancer (NSCLC) patients. Leukocytes from tumor tissues, distal normal lung tissues, and
peripheral blood mononuclear cells (PBMC) were analyzed for TIM-3 surface expression by flow cytometry. TIM-3 expression
on tumor-infiltrating lymphocytes (TILs) was correlated with clinicopathological parameters.
Conclusions: TIM-3 is highly upregulated on both CD4
+ and CD8
+ TILs from human lung cancer tissues but negligibly
expressed on T cells from patients’ peripheral blood. Frequencies of IFN-c
+ cells were reduced in TIM-3
+CD8
+ TILs compared
to TIM-3
2CD8
+ TILs. However, the level of TIM-3 expression on CD8
+ TILs failed to associate with any clinical pathological
parameter. Interestingly, we found that approximately 70% of TIM-3
+CD4
+ TILs expressed FOXP3 and about 60% of FOXP3
+
TILs were TIM-3
+. Importantly, TIM-3 expression on CD4
+ T cells correlated with poor clinicopathological parameters of
NSCLC such as nodal metastasis and advanced cancer stages. Our study reveals a new role of TIM-3 as an important immune
regulator in the tumor microenvironment via its predominant expression in regulatory T cells.
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Introduction
Tumor development induces antitumor immune responses.
Type 1 adaptive immune responses, mediated by Th1 cells and
CTLs, are thought to be a critical component of cell-mediated
immunity against cancer [1]. It has been well established,
however, that many tumor infiltrating T cells are in a state of
non-responsiveness due to the immune suppressive tumor
microenvironment [2,3]. Regulatory T cells and exhaustion of
effector T cells are thought to be two main T cell intrinsic
mechanisms that render ineffective anti-tumor immune responses
[2,4,5]. Multiple molecular pathways, such as TGFb, IL-10,
members of B7 family, are involved in establishing the state of
immune suppression within tumor [2,6,7,8]. Understanding of the
role of novel immune inhibitory pathways in mediating immune
tolerance in the tumor microenvironment should help improving
immunotherapy of cancer.
TIM-3 is expressed on Th1, Th17 cells, and CD8 T cells, but
not Th2 cells [9,10,11]. Interaction between TIM-3 and its ligand
galectin-9 inhibits Th1 and Th17 responses [12] and induces
peripheral tolerance [13,14], supporting an inhibitory role of
TIM-3 in T cell responses. TIM-3 expression also identifies
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30676exhausted T cells during chronic infection. TIM-3-expressing
CD4
+ and CD8
+ T cells produce reduced amounts of cytokine or
are less proliferative in response to antigen. Blockade of the TIM-
3 signaling pathway restores proliferation and enhances cytokine
production in HIV-1-specific T cells [15]. Recent studies have
supported an important role of TIM-3 T cell exhaustion in
cancer. Tim-3 and PD-1, another marker of T cell exhaustion,
are co-expressed on CD8 TILs in mice bearing transplanted
tumors as well as on NY-ESO-1-specific CD8
+ T cells in patients
with advanced melanoma [4,5]. TIM-3
+PD-1
+ T cells exhibit the
most severe exhausted phenotype as defined by failure to
proliferate and produce IL-2, TNF, and IFN-c. Blockade of
both Tim-3 and PD-1 pathways is more effective in controlling
tumor growth than targeting either pathway alone, suggesting
these two pathways work synergistically in establishing T cell
exhaustion [4,5].
In this study, we have investigated TIM-3 expression in TILs in
none small cell lung cancer (NSCLC). We have found that TIM-3
is expressed in both CD4
+ and CD8
+ TILs in lung cancer tissues.
Both TIM-3
+CD4
+ and TIM-3
+CD8
+ T cells produced much
reduced levels of IFN-c compared to those in TIM-3
2CD4
+ and
TIM-3
2CD8
+ T cells respectively. Interestingly, TIM-3 expres-
sion on CD4
+ T cells but not CD8
+ T cells correlated with poor
clinicopathological parameters of NSCLC such as nodal metastasis
and advanced cancer stages. Strikingly, approximately 70% of
TIM-3
+CD4
+ TILs expressed FOXP3 and about 60% of FOXP3
+
TILs were TIM-3
+. In contrast, TIM-3 was minimally expressed
in peripheral CD4
+ T cells, Tregs, and CD8
+ T cells. These data
suggest a novel role of TIM-3 in tumor associated regulatory T
cells and its importance in human cancer progression.
Materials and Methods
Selection of tissue samples
A total of 51 lung cancer tissue specimens were obtained from
pathologically confirmed and newly diagnosed non-small cell lung
cancer (NSCLC) patients who received operation from Oct. 2009
to May 2011 in Cardiothoracic Surgery Department of First
Affiliated Hospital, Soochow University in the present study. In
addition, 51 cases of adjacent normal tissues from non-malignant
portion were resected and chosen as controls. The normal tissues
were at least 5 centimeters away from the visible tumor mass.
Autologous peripheral blood mononuclear cells (PBMCs) were
isolated from whole blood by Ficoll density gradient centrifugation
before operation. This study was approved by the ethics
committee of the First Affiliated Hospital of Soochow University.
The data were analyzed anonymously and informed consent was
not required.
Figure 1. TIM-3 is highly expressed on both CD4
+ and CD8
+ tumor infiltrating T cells in lung cancer. Tumor infiltrating lymphocytes
(TILs) were harvested from lung cancer tissues, adjacent normal tissues, and peripheral blood monouclear cells (PBMCs) from whole blood of patients.
Cells were then stained for CD4, CD8, TIM-3 and PD-1. A. Representative dot-plots show TIM-3 expression on CD4
+ and CD8
+ T cells in various tissues
from lung cancer patients. Lymphocytes were gated for further analysis of CD4 and CD8 T cells. More than 90% CD4
+ or CD8
+ cells were CD3
+.B .
Summarized results of the percentage (%) of TIM-3 expression on CD4
+ and CD8
+ T cells from lung cancer patients are shown. Horizontal bars depict
the mean percentage of TIM-3 expression on CD4
+ and CD8
+ T cells. Error bars: s.e.m. C. Dual expression of TIM-3 and PD-1 on gated CD4
+ and CD8
+ T
cells is shown. The p-values were calculated using the one-way ANOVA.
doi:10.1371/journal.pone.0030676.g001
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Tumor tissue and adjacent normal tissue from the same patient
were minced and digested with collagenase digestion solution
(1 mg/ml collagenase IV (Sigma-Aldrich, St. Louis, MO, USA) in
RPMI1640) at 37uC for 45 min. The pieces were then transferred
to the steel mesh and single cell suspensions were obtained by
mechanical grind. TILs were further purified by the gradient as
per manufacturer protocol, washed and re-suspended in Hank’s
media for various analyses.
Mice
6–8-week-old female C57BL/6 mice were used in tumor
experiments. All animals were maintained under specific patho-
gen-free conditions in the animal facility at the University of
Pittsburgh or Soochow University. All animal work has been
approved by the Institution Animal Care and Use Committee at
the University of Pittsburgh (protocol number 0906824). For
tumor model experiments, mice were challenged with 2610
5
B16F0 cells i.d. and tumor samples were removed for analysis
around day 20 as described previously [16].
In vitro T cell stimulation
Naive T cells were purified from PBMCs of healthy donors
using depleting anti-CD45RO antibody and StemsepH human T
cell enrichment kit (StemCell technologies, Vancouver, British
Columbia, Canada). The purity of T cells was more than 90%.
Cells were stimulated with 1 mg/ml plate-bound anti-CD3 (clone
OKT3) and 2 mg/ml plate-bound anti-CD28 mAbs for up to
72 hours.
For isolating Tregs, PBMCs were stained with phycoerythrin-
cyanine Dye7 (PECY7) conjugated anti-CD4 mAb (RPA-T4) and
anti-CD25 phycoerythrin (PE) (BC96). A MoFlo cytometer
(Beckman-Coulter, Brea, CA USA) was used to isolate
CD4
+CD25
high cells. These cells were then stimulated with anti-
CD3 (1 mg/ml) and anti-CD28 (2 mg/ml) in the presence of IL-2
(200 U/mL, R&D Systems, Minneapolis, MN, USA). 24, 48, and
72 hours later, cells were harvested for further analysis.
Antibodies and Flow Cytometric Analysis
Directly conjugated anti-human antibodies against the following
surface molecules were used: anti-CD4 (RPA-T4) and anti-CD8
(RPA-T8) were obtained from Beckman Coulter. Anti-TIM-3
(344823), anti-PD-1(2H7), and anti-CD25 (BC96) were purchased
from R&D Systems. The following monoclonal antibodies specific
for mouse antigens were purchased from eBioscience (San Diego,
CA, USA): CD4 (GK1.5), CD8 (53-6.7), Tim-3 (RMT3-23) and
Foxp3 (FJK-16s). Flow cytometric analysis was performed using a
FACS flow cytometer.
For intracellular cytokine staining, human TILs were harvested
from lung cancer samples, stimulated with plate-bound anti-CD3
mAbs (1 mg/ml) and plate-bound anti-CD28 mAbs (2 mg/ml) for
16 hours and incubated for the last 3 hours with Brefeldin A
(10 mg/ml, Invitrogen, Carlsbad, CA, USA). Cells were trans-
ferred to a V-bottom plate, stained with anti-CD4 or anti-CD8 in
Hank’s buffer (containing 1% FCS), then fixed with fixation
medium, which was followed by permeabilization medium
(Invitrogen, Carlsbad, CA, USA). The cells were subsequently
stained with anti-IFN-c antibody (4S.B3, Biolegend, San Diego,
CA, USA). Cells producing IFN-c were examined with flow
cytometry.
For analysis of FOXP3 expression, TILs were first stained with
the anti-CD4-PECY7, anti-CD25-PECY5 and anti-TIM-3-PE or
anti-PD-1-PE, after fixation and permeabilization, cells were
incubated with FITC-conjugated anti-human FOXP3 (259D,
BioLegend, San Diego, CA, USA), based on the manufacturer’s
recommendations, and subjected to flow cytometric analysis.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0
software package (GraphPad Software, Inc., San Diego, USA).
Student’s t-test, one-way ANOVA and least significant difference
(LSD)-t test were used where appropriate. P-values less than 0.05
were considered as being statistically significant.
Results
Since TIM-3 is involved in T cell exhaustion, we decided to
investigate its expression on TILs in lung cancer specimens.
Leukocytes from tumor tissues, distal normal lung tissues, and
PBMC were analyzed for TIM-3 surface expression by flow
Figure 2. IFN-c production by TIM-3
+ and TIM-3
2 T cells in lung
cancer tissues. TILs were harvested from lung cancer tissue. Cells were
then stimulated with plate-bound anti-CD3 mAbs (1 mg/ml) and plate-
bound anti-CD28 mAbs (2 mg/ml) for 16 hours and incubated for the
last 3 hours with Brefeldin A (10 mg/ml). Cells producing IFN-c were
examined with intracellular cytokine staining and flow cytometry. (A
and B). Representative dot plots from one patient showed the
percentage of TIM-3
+IFN-c
+ and TIM-3
2IFN-c
+ within CD8
+ or CD4
+ T
cell compartment. Data shown are representative of six independent
experiments. C. The average percentage of IFN-c-producing CD8
+ or
CD4
+ T cells among TIM-3
+ and TIM-3
2 fractions is shown.
doi:10.1371/journal.pone.0030676.g002
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control IgG antibody (Figure S1). More than 90% of CD4
+ cells
were positive for CD3 after our purification procedure and
selection of lymphocyte gate during flow cytometric analysis. In
our lung cancer patient group, we have found that TIM-3 was
expressed on average at about 30% of the CD4
+ TILs and CD8
+
TILs (Figure 1A and 1B). The percentage of TIM-3
+CD4
+ and
TIM-3
+CD8
+ TILs in the distal normal lung tissues reduced to
approximately 18% and 15% respectively (Figure 1A and 1B). In
contrast, there was negligible expression of TIM-3 on the T cells in
blood from these patients (Figure 1A and 1B). Therefore, TIM-3
expression was specifically up-regulated on T cells in the normal
lung tissues and further increased in the cancer tissue. A recent
report showed that, in PBMC isolated from advanced melanoma
patient, a fraction of PD-1
+ NY-ESO-1–specific CD8
+ T cells co-
expressed TIM-3 and PD-1 and these cells were more dysfunc-
tional than TIM-3
2PD-1
+ and TIM-3
2PD-1
2 counterparts [4].
We then studied the PD-1 and TIM-3 expression on TILs from
lung cancer tissues. PD-1 was expressed in more than 65% of TILs
from both normal and cancer lung tissues (Figure 1C). Majority of
the TIM-3
+ TILs were PD-1
+ in the lung tissues. In contrast, 10%
of T cells in peripheral blood were positive for PD-1 (Figure 1C).
Thus, we found that large numbers of TIM-3
+PD-1
+ T cells were
enriched in lung cancer tissues. This is consistent with the fact that
many of T cells in the cancer tissues are dysfunctional likely due to
exhaustion or anergy.
Since it has been shown that antigen-specific TIM-3
+CD8
+ T
cells are functionally exhausted in chronic infection and cancer
patients, we decided to study whether TIM-3 also marked
dysfunctional T cells in TILs in lung cancer tissues. TILs were
stimulated with anti-CD3 and anti-CD28 for 16 h and analyzed
for the IFN-c production by flow cytometry. We have found that
on average 5% TIM-3
2CD8
+TILs are IFN-c
+ upon ex-vivo
stimulation with anti-CD3 (Figure 2A, 2C). In contrast, the
Figure 3. TIM-3 expression on CD4
+ TILs and Treg. TILs were harvested from lung cancer tissue. Cells were then stained for CD4, TIM-3, and
FOXP3 (A) or CD4, PD-1, and FOXP3 (B). Lymphocytes were gated for further analysis of CD4 and CD8 T cells. The percentage of each population
within CD4
+ T cell compartment was indicated. Data shown are representative of five independent experiments.
doi:10.1371/journal.pone.0030676.g003
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3
+CD8
+ TILs (Figure 2A, 2C). Thus, our data are consistent with
the idea that TIM-3 marks functional exhaustion of CD8 T cell in
human cancer tissues, in keep with the recent finding using
transplant mouse tumor model [5].
Besides CD8
+ TILs, TIM-3 was found expressed on CD4
+ TILs
in human lung cancer (Figure 1) as well as in the mouse
transplanted tumor [5]. Tim-3 was also highly expressed on the
Th1 and Th17 cells and important for inhibiting the function of
these cells [10]. Whether TIM-3 marks CD4
+ T cell dysfunction is,
however not certain. We then set out examining the frequency of
IFN-c-producing CD4
+ TILs with respect to TIM-3 surface
expression. We have found about 2% of TIM-3
2CD4
+ TILs were
IFN-c producers upon ex vivo stimulation with anti-CD3
(Figure 2B). In contrast, the percentage of IFN-c
+ cells was
significantly reduced in TIM-3
+CD4
+ TILs (Figure 2B and 2C).
It is well established that regulatory T cells are a predominant
population of CD4
+ T cells among TILs [3]. Because Tregs are
also functionally anergic, we then decided to determine whether
TIM-3 is expressed in regulatory T cells among TILs using
FOXP3 as the marker. To our surprise, although about 17% of
the CD4
+ TILs were FOXP3
+ Tregs, about 70% of TIM-3
+CD4
+
TILs were FOXP3
+ (Fig. 3A). In addition, about 60% of the
FOXP3
+CD4
+ TILs expressed TIM-3 on their surfaces (Fig. 3A).
Thus, TIM-3
+CD4
+ T cells were predominantly Tregs and most
of Tregs within lung cancer TILs highly up-regulated TIM-3
expression. In line with these data, all FOXP3
+CD4
+ TILs express
PD1 (Fig. 3B). In contrast to high expression of TIM-3 in TILs,
minimal expression of TIM-3 was found on neither conventional
T cells nor Tregs in peripheral blood (data not shown).
Since TIM-3 was shown to be upregulated in T cells upon in
vitro culture in the presence of TCR stimulation [10], we decided
to examine whether Tregs could be stimulated to express TIM-3.
As a control, human CD4
+ and CD8
+ T cells were stimulated with
anti-CD3 and anti-CD28 for 72 h. Every 24 h, we examined
TIM-3 and PD-1 expression. Both PD-1 and TIM-3 were
upregulated at around 48 h and further up-regulated at 72 h in
both CD4
+ and CD8
+ T cells (Fig. 4A and 4B). We then tested
whether TIM-3 could be similarly up-regulated in regulatory T
cells. We enriched human Tregs by isolating CD4
+CD25
high T
cells using fluorescence-activated cell sorting (FACS). Then we
stimulated these T cells with anti-CD3 and anti-CD28 in the
presence of IL-2 for 72 h. The expression of TIM-3 and FOXP3
was examined at 48 h and 72 h. TIM-3 is expressed at negligible
Figure 4. TIM-3 and PD-1 were up-regulated upon T cell activation. (A and B). Human naı ¨ve T cells were purified from PBMCs of health
donors. Cells were then stimulated with plate-bound anti-CD3 plus anti-CD28 mAb. 24, 48 and 72 hours later, cells were collected and stained for
CD4, CD8, TIM-3 and PD-1. The expression of PD-1 and TIM-3 was analyzed by flow cytometry on gated CD4
+ (A) or CD8
+ (B) T cells. C. CD4
+CD25
high T
cells were isolated from peripheral blood by FACS. These cells were then stimulated with anti-CD3 and anti-CD28 in the presence of IL-2 (200 U/mL).
24, 48 and 72 hours later, cells were harvested and stained for CD4, TIM-3 and FOXP3. The expression of TIM-3 on CD4
+FOXP3
+ T cells is shown. Data
are representative of three independent experiments.
doi:10.1371/journal.pone.0030676.g004
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+, CD8
+ T cell in TILs in patients with NSCLC.
CD4
+ T cell CD8
+ T cell CD4
+/CD8
+
N= mean±SD P mean±SD P mean±SD P
Gender
male 40 21.76%610.33% 18.65%610.86% 1.48%60.96%
female 11 19.33%69.72% 0.4482 11.23%66.38% 0.0362 1.93%60.85% 0.168
Age
#60 19 22.12%611.33% 18.38%610.11% 1.52%60.99%
.60 32 20.63%69.44% 0.6163 16.11%610.77% 0.459 1.61%60.93% 0.741
Histological subtype
Squamous cell carcinoma 22 21.75%612.20% 18.22%611.02% 1.44%60.88%
Adenocarcinoma 18 20.48%68.28% 16.36%610.45% 1.66%61.01%
others 11 21.43%69.10% 0.9263 15.57%69.98% 0.766 1.73%61.01% 0.657
Tumor size
T1+T2 3+31 22.48%610.64% 15.77%68.31% 1.67%60.90%
T3+T4 11+6 18.80%68.93 0.229 19.45%613.70% 0.320 1.41%61.02% 0.364
Lymph node metastasis
N0 22 22.28%610.09% 18.49%610.78% 1.45%60.73%
N1 11 22.52%68.41% 19.08%610.95% 1.53%60.83%
N2 18 19.37%611.31% 0.6088 14.28%69.79% 0.353 1.74%61.19% 0.647
Tumor stage
I+II 17+10 22.40%69.37% 18.34%610.91% 1.51%60.78%
III+IV 23+1 20.05%610.95% 0.4176 15.70%610.04% 0.378 1.65%61.10% 0.610
doi:10.1371/journal.pone.0030676.t001
Table 2. Clinical significance of Tim-3
+ TILs in patients with NSCLC.
CD4
+ T cells CD8
+ T cells
N= mean±SD P mean±SD P
Gender
male 40 29.95%610.17% 32.27%615.70%
female 11 23.85%611.13% 0.09 24.65%614.90% 0.156
Age
#60 19 27.83%612.32% 27.15%612.88%
.60 32 29.10%69.58% 0.682 32.70%617.01% 0.226
Histological subtype
Squamous cell carcinoma 22 27.18%68.71% 26.51%614.92%
Adenocarcinoma 18 30.71%613.07% 30.19%611.14%
others 11 28.14%69.87% 0.577 39.58%620.69% 0.075
Tumor size
T1+T2 3+31 26.64%610.29% 30.02%616.95%
T3+T4 11+6 32.62%610.30% 0.056 31.84%613.24% 0.701
Lymph node metastasis
N0 22 25.06%69.88% 28.84%615.74%
N1 11 27.75%66.64% 35.37%619.39%
N2 18 33.53%611.84% 0.036 29.92%613.37% 0.525
Tumor stage
I+II 17+10 25.63%69.31% 31.06%617.87%
III+IV 23+1 32.00%611.08% 0.030 30.15%613.21% 0.839
doi:10.1371/journal.pone.0030676.t002
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+ T cells and Tregs (data not
shown). Compared to unstimulated T cells, TIM-3 expression was
significantly up-regulated at 48 h and further increased at 72 h
(Fig. 4C). At 72 h about 25% of the FOXP3
+ T cells were TIM-3
positive (Fig. 4C). Collectively, these data suggest that TIM-3 is
up-regulated on both conventional T cells and Tregs upon
stimulation via TCR.
Since TIM-3 ishighly expressed inTILsisolated fromlung cancer
tissues, we then determined whether TIM-3 expression had any
clinical significance by correlating TIM-3 expression with clinical
pathological parameters. We have found the percentage of CD4
+
and CD8
+ T cells within TILs was not associated with any clinical
pathological parameters. The ratio of CD4 versus CD8 also failed to
show any clinical significance (Table 1). In addition, the frequency of
TIM-3 on CD8 T cells did not show any clinical significance
(Table 2). In contrast, the higher frequency of TIM-3
+CD4
+ TILs
showed significant association with lymph node metastasis and more
advanced cancer stages (Table 2). Thus, the TIM-3 expression on
CD4
+ TILs is associated with lung cancer progression.
In addition to human FOXP3
+ TILs, we examined the Tim-3
expression on mouse Foxp3
+ TILs. We used the B16 model
because Tim-3
+CD4
+ TILs were recently described in this model
[5]. Within the B16 tumor, we found about 50% of the
Foxp3
+CD4
+ TILs expressed Tim-3 (Fig. 5). In contrast,
Foxp3
2CD4
+ TILs expressed negligible levels of Tim-3 (Fig. 5).
Tim-3 was expressed at minimal levels in spleen and lymph node
CD4
+ T cells irrespective of Foxp3 expression (Fig. 5). Thus, Tim-
3 is predominantly present on a subset of Foxp3
+CD4
+ regulatory
T cells in both human and mouse tumors.
Discussion
In this study, we examined TIM-3 expression in TILs from
NSCLC specimens. We found high levels of TIM-3 expression on
both CD4
+ and CD8
+ TILs. Importantly, even though TIM-3
surface expression has been reported to indicate a functionally
anergic state of CD8
+ TILs, we found that TIM-3 expression on
CD8
+ TILs failed to associate with clinicopathological parameters
in lung cancer, however the frequency of TIM-3 expression on
CD4
+ TILs did associate with lymph node metastasis and more
advanced cancer stages. Further analysis revealed that TIM-
3
+CD4
+ T cells were predominantly FOXP3
+ and majority of
FOXP3
+CD4
+ T cells expressed TIM-3. Our study reveals a new
role of TIM-3 in the tumor microenvironment via its predominant
expression in regulatory T cells.
It is interesting that we have found expression of TIM-3 on a
large proportion of Tregs within lung cancer tissues. Our data
mining also revealed that Tim-3 mRNA was expressed in natural
Figure 5. Expression of Tim-3 on TILs in mouse model of transplantable tumor. 6–8-week-old C57BL/6 mice were inoculated with 2610
5
B16F0 cells i.d., tumor samples, spleens, and lymph nodes were removed when tumor sizes reached around 15 mm in diameters on day 20. TILs,
splenocytes, and lymph node cells were isolated for analysis by flow cytometry. Tim-3 expression on mouse CD4
+Foxp3
+ or CD4
+Foxp3
2 T cells is
shown. Data shown are representative of five independent experiments.
doi:10.1371/journal.pone.0030676.g005
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+CD4
+ T cells which have been adoptively transferred to
Rag1 deficient mice and Foxp3 is required for Tim-3 expression in
these Treg cells (Figure S2) [17], suggesting Tim-3 expression in
Tregs might be an integral part of Foxp3-regulated network within
natural Tregs. We have further shown that TIM-3 is not
constitutively expressed by Tregs in the human peripheral blood
but can be induced upon TCR stimulation. The reason that TIM-3
is highly expressed in FOXP3
+CD4
+ TILs might be due to constant
stimulation by tumor associated antigens within the tumor site.
The exact role of TIM-3 in the tumor infiltrating Tregs is still
not known. Our data suggest that TIM-3
+ Tregs in lung cancer
tissues could be derived from natural Tregs upon chronic TCR
stimulation by tumor antigens. PD-1 ligand B7-H1 and TIM-3
ligands such as galectin-9 and apoptotic cells within the tumor
tissue might be important for maintaining the number and
function of TIM-3
+PD-1
+ Tregs. In the transplantation setting,
Tim-3 was shown to regulate allospecific Treg activation [14]. It
was shown that Tim-3-Tim-3L-sensitive pathway was involved in
the functional generation of donor-specific Tregs upon adminis-
tration of tolerizing treatments [14]. Consistent with this idea,
Tim-3 has recently been reported to be expressed in about 15% of
Foxp3
+Treg cells in the spleen during allo-transplantation [18].
Our study, by revealing high levels of TIM-3 expression on Tregs
within human tumor, suggests that TIM-3 might play a direct role
in the functional maturation of tumor infiltrating Tregs by
delivering a signal within Tregs or might be important for
maintaining the immunosuppressive function of these Tregs in the
tumor microenvironment.
Besides natural Tregs, TIM-3 and PD-1 can also play a role in
the generation of adaptive Tregs. In fact, PD-1 ligand was shown
to be involved in the generation of adaptive Tregs in the tumor
draining lymph nodes [19]. Galectin-9 was shown to modestly
increase the Foxp3 expression in vitro model of Tregs induction by
TGF-b [18,20]. Whether the Tregs found in our studies are
adaptive or natural Treg will be subject to further study.
TIM-3 has emerged as a promising target for cancer
immunotherapy [21]. Recent studies have focused on the role of
TIM-3 expression on CD8
+ T cells in peripheral blood as well as
within tumors [4,5]. These study elegantly demonstrated that
TIM-3 marks functionally exhausted CD8
+ T cells and is likely
responsible for failure of immunosurveillance and tumor vaccina-
tion. Our study shows that expression of TIM-3 on CD4
+ TILs
cells significantly associated with worse clinical pathological
parameters in lung cancer. Therefore, TIM-3 likely plays a
significant role in tumor progression by maintaining the tumor
immunosuppressive environment via Tregs. Further characteriza-
tion of TIM-3 expression and function within various TILs subsets
should improve our knowledge of underlying mechanisms of TIM-
3-mediated immunosuppression within tumor microenvironment.
Supporting Information
Figure S1 TIM-3 expression by flow cytometry. Tumor
infiltrating lymphocytes (TILs) were harvested from lung cancer
tissues, adjacent normal tissues, and peripheral blood monouclear
cells (PBMCs) from whole blood of patients. Cells were then
stained for CD4 and TIM-3 or CD4 plus a control IgG antibody.
Cells in the lymphocyte gate were further analyzed for CD4 and
TIM-3 expression.
(PPT)
Figure S2 Tim-3 expression in native Tregs and its
dependence on Foxp3. NCBI GEO profile database was
queried for Tim-3 expression in Tregs. One result showed that
Tim-3 is down-regulated in Foxp3 deficient native Tregs as shown
here. DataSet Record GDS2525.
(PPT)
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